Cargando…
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
Fludarabine, cyclophosphamide and rituximab (FCR) was compared to bendamustine and rituximab (BR) in an international, randomized, open label, phase 3 trial in 561 previously untreated, fit patients with chronic lymphocytic leukemia (CLL) without del (17p). Primary endpoint was progression free surv...
Autores principales: | Kutsch, Nadine, Bahlo, Jasmin, Robrecht, Sandra, Franklin, Jeremy, Zhang, Can, Maurer, Christian, De Silva, Nisha, Lange, Elisabeth, Weide, Rudolf, Kiehl, Michael G., Sökler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Köchling, Georg, Plöger, Christoph, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Döhner, Hartmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl-Anton, Böttcher, Sebastian, Stilgenbauer, Stephan, Fink, Anna Maria, Hallek, Michael, Eichhorst, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000471/ https://www.ncbi.nlm.nih.gov/pubmed/32072150 http://dx.doi.org/10.1097/HS9.0000000000000336 |
Ejemplares similares
-
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
por: Herling, Carmen D., et al.
Publicado: (2020) -
P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023) -
Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020) -
S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023) -
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
por: Jaramillo, Sonia, et al.
Publicado: (2019)